Publication Name	World Journal of Hepatology
Manuscript ID	19178
Country	United States

Received	2015-04-30 14:28
Peer-Review Started	2015-05-08 10:12
To Make the First Decision	2015-08-31 16:43
Return for Revision	2015-09-08 09:42
Revised	2015-10-24 21:49
Second Decision	2015-11-09 10:55
Accepted by Journal Editor-in-Chief	2015-11-12 01:18
Accepted by Company Editor-in-Chief	2015-11-25 15:44
Articles in Press	2015-11-25 15:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-12-01 09:08
Publish the Manuscript Online	2015-12-10 15:03

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Advances in cirrhosis: Optimizing the management of hepatic encephalopathy
Manuscript Source	Invited Manuscript
All Author List	Andy Liu, Ryan B Perumpail, Radhika Kumari, Zobair M Younossi, Robert J Wong and Aijaz Ahmed
Funding Agency and Grant Number
Corresponding Author	Aijaz Ahmed, MD, Associate Professor of Medicine, Medical Director Liver Transplant Program, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 750 Welch Road, Suite 210, Palo Alto, Stanford, CA 94305, United States. aijazahmed@stanford.edu
Key Words	Overt hepatic encephalopathy; Lactulose; Rifaximin; Hepatic encephalopathy; Covert hepatic encephalopathy
Core Tip	Hepatic encephalopathy (HE) is a major complication of cirrhosis resulting in significant socioe-conomic burden, morbidity, and mortality. Management of acute overt HE (OHE) involves institution of lactulose, the preferred first-line therapy. In addition, prompt recognition and treatment of precipitating factors may result in complete resolution of acute episodes of OHE. Treatment goals include improvement of daily functioning and prevention of OHE recurrence. For secondary prophylaxis, intolerance to indefinite lactulose therapy may lead to non-adherence and has been identified as a precipitating factor for recurrent OHE. Rifaximin is an effective add-on therapy to lactulose for treatment and prevention of recurrent OHE.
Publish Date	2015-12-10 15:03
Citation	Liu A, Perumpail RB, Kumari R, Younossi ZM, Wong RJ, Ahmed A. Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World J Hepatol 2015; 7(29): 2871-2879
URL	http://www.wjgnet.com/1948-5182/full/v7/i29/2871.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i29.2871

Full Article (PDF)	WJH-7-2871.pdf
Full Article (Word)	WJH-7-2871.doc
Manuscript File	19178-Review.docx
Answering Reviewers	19178-Answering reviewers.pdf
Audio Core Tip	19178-Audio core tip.wma
Conflict-of-Interest Disclosure Form	19178-Conflict-of-interest statement.pdf
Copyright License Agreement	19178-Copyright assignment.pdf
Peer-review Report	19178-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	19178-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	19178-Scientific misconduct check.pdf
Scientific Editor Work List	19178-Scientific editor work list.pdf